Work

Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.e19005

Authors: Glen J. Weiss, Jasgit C. Sachdev, Jeffrey R. Infante, Monica M. Mita, Ronald B. Natale, Hendrik-Tobias Arkenau, Keith Wilcoxen, Vikram Kansra, Haley Laken, Lorraine Hughes, David G. Brooks, Robert E. Martell, Stephen Patrick Anthony

Institutions: Western Regional Medical Center, Translational Genomics Research Institute, Sarah Cannon, Tennessee Oncology, Cedars-Sinai Medical Center, Sarah Cannon Research Institute, Tesaro (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601147387

Cites:

Cited by: 14

Related to: 10